Skip to content

    HALOZYME THERAPEUTICS (HALO) stock price & financials

    View HALO earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+44.0% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $290.08M
    $298.01M
    $264.86M
    $325.72M
    $354.26M
    +22.1%
    $451.77M
    +51.6%
    $376.71M
    +42.2%
    $481.00M
    +47.7%
    Strengthening
    Operating Profit
    $163.20M
    $175.50M
    $141.53M
    $202.44M
    $217.92M
    +33.5%
    -$92.89M
    -152.9%
    $184.52M
    +30.4%
    $287.65M
    +42.1%
    Weakening
    Net Profit
    $137.01M
    $137.01M
    $118.09M
    $165.16M
    $175.22M
    +27.9%
    -$141.59M
    -203.3%
    $150.05M
    +27.1%
    $229.91M
    +39.2%
    Weakening
    EPS
    $1.08
    $0.96
    $1.36
    $1.49
    +38.0%
    $1.27
    +32.3%
    $1.96
    +44.1%
    Strengthening
    Other Income
    Interest
    $4.52M
    $4.54M
    $4.53M
    $4.39M
    $4.30M
    -5.0%
    $4.91M
    +8.2%
    $5.51M
    +21.7%
    $5.59M
    +27.2%
    Strengthening
    Depreciation
    Profit before Tax
    $165.15M
    $178.21M
    $143.83M
    $204.94M
    $218.96M
    +32.6%
    -$100.85M
    -156.6%
    $180.33M
    +25.4%
    $284.90M
    +39.0%
    Weakening
    MarginsOPM
    56.3%
    58.9%
    53.4%
    62.1%
    61.5%
    +9.3%
    -20.6%
    -134.9%
    49.0%
    -8.3%
    59.8%
    -3.8%
    Weakening
    Tax
    17.0%
    23.1%
    17.9%
    19.4%
    20.0%
    +17.2%
    -40.4%
    -274.7%
    16.8%
    -6.1%
    19.3%
    -0.6%
    Weakening
    ReturnsROIC
    90.5%
    90.5%
    78.0%
    109.1%
    115.8%
    +27.9%
    -93.5%
    -203.3%
    99.1%
    +27.1%
    151.9%
    +39.2%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$57.94M$120.18M$147.70M$118.72M$234.19M$118.37M$115.85M$133.82M$163.14M
    Short-Term Investments
    Total Current Assets$427.85M$543.44M$554.76M$926.29M$739.01M$746.42M$1.09B$825.21M$933.02M
    Net PP&E$7.46M$14.70M$10.59M$8.79M$75.57M$74.94M$75.03M$82.14M$84.27M
    Goodwill$0$409.05M$416.82M$416.82M$580.36M$581.73M
    Intangibles$0$546.65M$472.88M$401.83M$981.47M$922.44M
    Total Assets$440.25M$565.87M$579.92M$1.10B$1.84B$1.73B$2.06B$2.53B$2.58B
    LiabilitiesTotal Current Liabilities$149.36M$85.64M$421.38M$117.15M$130.79M$112.49M$139.10M$177.09M$344.44M
    Short-Term Debt$91.51M$19.54M$397.23M$89.42M$13.33M$0$0$0$208.97M
    Long-Term Debt$34.87M$383.05M$0$787.25M$1.49B$1.50B$1.51B$2.14B$1.94B
    Long-Term Leases
    Total Liabilities$191.36M$474.11M$428.88M$907.48M$1.67B$1.65B$1.70B$2.48B$2.43B
    EquityCommon Stock & APIC$145.0K$137.0K$135.0K$138.0K$135.0K$127.0K$123.0K$118.0K$114.0K
    Retained Earnings-$531.44M-$603.68M-$474.59M-$58.91M$143.22M$90.55M$359.87M$54.79M$151.26M
    Total Equity$248.89M$91.77M$151.05M$196.95M$169.80M$83.81M$363.82M$48.81M$143.54M
    HighlightsNet Cash / (Debt)-$68.44M-$282.41M-$249.53M-$757.96M-$1.27B-$1.38B-$1.39B-$2.01B-$1.98B

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$49.50M-$85.42M$55.45M$299.44M$240.11M$388.57M$479.06M$651.56M$818.60M
    Cash from Investing$2.49M-$5.55M$78.35M-$406.29M-$487.00M-$96.91M-$262.72M-$545.81M-$605.72M
    Cash from Financing-$63.80M$153.22M-$106.28M$77.86M$362.37M-$407.99M-$218.86M-$85.17M-$110.75M
    SummaryCapital Expenditure-$4.66M-$4.04M-$2.50M-$1.46M-$4.81M-$15.29M-$10.70M-$6.97M-$12.37M
    Free Cash Flow-$54.16M-$89.46M$52.95M$297.98M$235.30M$373.28M$468.37M$644.59M$806.22M
    FCF Margin-35.7%-45.6%19.8%67.2%35.6%45.0%46.1%46.2%48.5%

    Ratios